中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
18期
110-111
,共2页
托吡酯%癫痫%疗效%不良反应
託吡酯%癲癇%療效%不良反應
탁필지%전간%료효%불량반응
Topiramate%Epilepsy%Efficacy%Adverse reaction
目的 研究总结托吡酯治疗癫痫患者的临床疗效及不良反应,为临床提供可参考依据.方法 纳入我院2010年1月~2013年7月癫痫患者52例,所有患者采用托吡酯进行治疗,随访3个月、半年、一年和两年的临床效果,并对其不良反应现象进行总结.结果 经过随访发现, 3个月时有2例患者因为不耐受退出实验.剩余50例患者3个月总有效率为54.0%,半年总有效率为70.0%,一年总有效率为74.0%,两年总有效率为80.0%,总有效率呈逐渐增长趋势,两年总有效率跟治疗3个月总有效率对比差异显著, < 0.05;不良反应情况除了2例不耐受(主要是出现异常兴奋和反应迟钝),还有23例出现其他症状,不良反应发生率为48.08%.结论 托吡酯治疗癫痫患者的临床疗效随着用药时间的延长而提高,对于出现不耐受或严重不良反应的患者应停止用该药物治疗.
目的 研究總結託吡酯治療癲癇患者的臨床療效及不良反應,為臨床提供可參攷依據.方法 納入我院2010年1月~2013年7月癲癇患者52例,所有患者採用託吡酯進行治療,隨訪3箇月、半年、一年和兩年的臨床效果,併對其不良反應現象進行總結.結果 經過隨訪髮現, 3箇月時有2例患者因為不耐受退齣實驗.剩餘50例患者3箇月總有效率為54.0%,半年總有效率為70.0%,一年總有效率為74.0%,兩年總有效率為80.0%,總有效率呈逐漸增長趨勢,兩年總有效率跟治療3箇月總有效率對比差異顯著, < 0.05;不良反應情況除瞭2例不耐受(主要是齣現異常興奮和反應遲鈍),還有23例齣現其他癥狀,不良反應髮生率為48.08%.結論 託吡酯治療癲癇患者的臨床療效隨著用藥時間的延長而提高,對于齣現不耐受或嚴重不良反應的患者應停止用該藥物治療.
목적 연구총결탁필지치료전간환자적림상료효급불량반응,위림상제공가삼고의거.방법 납입아원2010년1월~2013년7월전간환자52례,소유환자채용탁필지진행치료,수방3개월、반년、일년화량년적림상효과,병대기불량반응현상진행총결.결과 경과수방발현, 3개월시유2례환자인위불내수퇴출실험.잉여50례환자3개월총유효솔위54.0%,반년총유효솔위70.0%,일년총유효솔위74.0%,량년총유효솔위80.0%,총유효솔정축점증장추세,량년총유효솔근치료3개월총유효솔대비차이현저, < 0.05;불량반응정황제료2례불내수(주요시출현이상흥강화반응지둔),환유23례출현기타증상,불량반응발생솔위48.08%.결론 탁필지치료전간환자적림상료효수착용약시간적연장이제고,대우출현불내수혹엄중불량반응적환자응정지용해약물치료.
Objective Research summary clinical eficacy and adverse reactions of topiramate in treatment of epilepsy patients, provides the reference for clinical.Methods 52 cases included in our hospital in 2010 January~2013 July epilepsy patients. Al patients received topiramate treatment, folow-up of 3 months, half a year, one year and two years clinical efect and the adverse reaction phenomenon were summarized in this paper.Results 2 patients were folowed up for 3 months. The remaining 50 patients 3 months the total eficiency was 54.0%, the first half of the total efective rate was 70.0%, one year the total eficiency was 74.0%, two years the total efective rate was 80.0%, the total eficiency was gradualy increasing trend, two years the total eficiency is related to the treatment of 3 months the total eficiency had significant diferences, P < 0.05. Adverse reactions except for the 2 cases of intolerance (mainly is excited and unresponsive), and 23 cases had other symptoms, adverse reactions occurred rate was 48.08%.Conclusion The clinical eficacy of topiramate in treatment of epilepsy patients with the extension of treatment time and improve, for intolerance or serious adverse reactions of the patients should stop treatment with the drug.